Pozen receives first regulatory approval; MT 100 given go-ahead for migraine in U.K.

New York, Nov. 28 - Pozen, Inc. said it received marketing authorization for MT 100 for the acute treatment of migraine from the U.K. Medicines and Healthcare Products Regulatory Agency.

"The authorization for MT 100 by the MHRA is a milestone event for Pozen as it's our first regulatory approval for one of our drug candidates," said John R. Plachetka, chairman, president and chief executive officer of Pozen, in a news release.

"We are currently seeking a partner who can bring MT 100 to market in the U.K. and eventually in other countries outside the U.S."

MT 100 is an oral first-line treatment for migraine. It is a patented sequential release tablet containing two approved drugs, naproxen sodium, which relieves pain and reduces inflammation, and metoclopramide, which accelerates the absorption of naproxen and contributes to the relief of migraine.

Pozen is a Chapel Hill, N.C., pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.